CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS NOT MATERIAL AND (I) WOULD BE COMPETITIVELY HARMFUL TO THE REGISTRANT IF PUBLICLY DISCLOSED OR (II) IS INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL....Collaboration Expansion Agreement • March 23rd, 2022 • Recursion Pharmaceuticals, Inc. • Biological products, (no disgnostic substances)
Recursion Pharmaceuticals, Inc., a Delaware corporation with offices at 41 S Rio Grande Street, Salt Lake City, UT 84101 (“Recursion”) and Bayer AG, a German corporation with offices at 42096 Wuppertal, Germany (“Bayer”) (each of Recursion and Bayer a “Party” and together the “Parties”) entered into a Research Collaboration and Option Agreement dated August 28th, 2020 (the “Agreement”) and now wish to expand the Agreement (the “Expansion”) effective as of December 1st, 2021 (the “Expansion Effective Date”) as described below.
AMENDMENT NO. 2 TO COLLABORATION EXPANSION AGREEMENTCollaboration Expansion Agreement • March 15th, 2019 • Athersys, Inc / New • Pharmaceutical preparations
This Amendment No. 2 (this “Amendment”) to the Collaboration Expansion Agreement (the “Agreement”) is made on December 6, 2018, by and among ABT Holding Company, a Delaware corporation (“ATHX”), Athersys, Inc., a Delaware corporation (“Athersys”), and HEALIOS K.K., a Japanese company (“Healios”). Capitalized terms used herein without definition shall have the meanings ascribed to such terms in the Agreement.
AMENDMENT NO. 1 TO COLLABORATION EXPANSION AGREEMENTCollaboration Expansion Agreement • November 6th, 2018 • Athersys, Inc / New • Pharmaceutical preparations
This Amendment No. 1 (this “Amendment”) to the Collaboration Expansion Agreement (the “Agreement”) is made on August 31, 2018, by and among ABT Holding Company, a Delaware corporation (“ATHX”), Athersys, Inc., a Delaware corporation (“Athersys”), and HEALIOS K.K., a Japanese company (“Healios”). Capitalized terms used herein without definition shall have the meanings ascribed to such terms in the Agreement.
COLLABORATION EXPANSION AGREEMENTCollaboration Expansion Agreement • August 9th, 2018 • Athersys, Inc / New • Pharmaceutical preparations • New York
This Collaboration Expansion Agreement (this “Agreement”), dated as of 6 June 2018 (the “Effective Date”), is made and entered into between ABT Holding Company (“ATHX”), a Delaware corporation having its principal place of business at 3201 Carnegie Avenue, Cleveland, OH 44115 and wholly-owned subsidiary of Athersys, Inc. (“Athersys”), and HEALIOS K.K. (“Healios”), a Japanese company having its principal place of business at World Trade Center Bldg. 15F, 2-4-1 Hamamatsucho, Minato-ku, Tokyo 105-6115 Japan, and solely with respect to the guarantee set forth herein, Athersys. ATHX and Healios may be referred to individually as a “Party” and collectively as the “Parties”.
AMENDMENT NO. 3 TO COLLABORATION EXPANSION AGREEMENTCollaboration Expansion Agreement • March 15th, 2019 • Athersys, Inc / New • Pharmaceutical preparations
This Amendment No. 3 (this “Amendment”) to the Collaboration Expansion Agreement (the “Agreement”) is made on December 14, 2018, by and among ABT Holding Company, a Delaware corporation (“ATHX”), Athersys, Inc., a Delaware corporation (“Athersys”), and HEALIOS K.K., a Japanese company (“Healios”). Capitalized terms used herein without definition shall have the meanings ascribed to such terms in the Agreement.
